Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


ASH 2015: Capitalising on recent advances in HL – R/R HL in the brentuximab vedotin era. Professor Ajay Gopal, Seattle Cancer Care Alliance, WA, USA. Dr Robert Chen, City of Hope, Duarte, CA, USA and Professor John Sweetenham, Huntsman Cancer Institute, Saltlake City, USA., discuss where they see the optimal setting for use of brentuximab vedotin following updates at ASH 2015. Click on the video image to view.

Written by | 31 Dec 2015 | All Medical News


Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.